Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2022-05-10 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of April 30, 2022. This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure transparency. While it touches upon share capital, it is not a general capital change announcement (SHA) or a major shareholding notification (MRQ) which usually reports changes by specific entities crossing thresholds. Instead, it is a mandatory monthly disclosure of the total count. Among the provided codes, this specific monthly disclosure about the total number of shares and voting rights aligns most closely with the requirements covered under general regulatory reporting, which often falls under 'Regulatory Filings' (RNS) or, if interpreted as a notification of the current capital structure, sometimes relates to share capital changes. However, given the specific nature of reporting total voting rights monthly, and the lack of a dedicated code for 'Total Voting Rights Disclosure', it is best classified as a general Regulatory Filing (RNS). It is not an ER, CT, 10-K, or IR. It is a formal, periodic regulatory update.
2022-05-10 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is explicitly titled "STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL" and cites French Commercial Code and AMF regulations regarding voting rights. It provides a table detailing the 'Number of Shares Outstanding' and 'Total number of voting rights' as of a specific date (April 30, 2022). This content directly relates to the structure of shareholder voting power, which is a key component of corporate governance and shareholder rights announcements. While it is a regulatory disclosure, it is not a general regulatory filing (RNS) or a report itself (like 10-K or IR). It is a specific announcement concerning voting rights and share capital structure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit, as it deals with the official count of voting rights, even if it's not the result of a specific vote, but rather the current standing.
2022-05-10 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly states: "NANOBIOTIX ANNONCERA SES RÉSULTATS FINANCIERS DU PREMIER TRIMESTRE 2022, LE 18 MAI 2022" (NANOBIOTIX WILL ANNOUNCE ITS FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 18, 2022). It details the date and time for the release of financial results and the subsequent conference call. This content perfectly matches the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it mentions the full results will be discussed later, this document itself is the announcement of those results.
2022-05-04 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "*PRESS RELEASE*" and its primary purpose is to announce the date (May 18, 2022) when the company will report its financial results for the first quarter of 2022, followed by a conference call on May 19, 2022. This structure—announcing the date of the upcoming financial results release and subsequent call—is the defining characteristic of an Earnings Release (ER). It is not the full financial report itself (which would be an IR or 10-K), nor is it the transcript of the call (CT). It is the initial announcement of the results period.
2022-05-04 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that new data on the product NBTXR3 will be presented at the ASCO 2022 annual meeting. It details the abstracts to be presented and provides background information on the product and the company. This is a standard announcement regarding upcoming scientific data presentation, not the full financial report (10-K, IR), a formal earnings release (ER), or a proxy statement. Since it is an announcement about company news and scientific updates, and it doesn't fit the specific categories like DIV, DIRS, or MANG, it falls best under the general Regulatory Filings category (RNS) as a broad corporate/scientific update, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-standard filings, although it is highly focused on clinical data presentation. Since it is a press release announcing data presentation, RNS is the most appropriate general classification for this type of corporate communication that isn't a core financial report or a specific event material.
2022-05-02 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces that data regarding the product candidate NBTXR3 will be presented at the 2022 ASCO Annual Meeting. It details the abstracts accepted for presentation and provides background information on the product and the company. This type of announcement, focusing on upcoming scientific presentations or key data releases outside of mandatory periodic financial filings (like 10-K or IR), is best classified as an Earnings Release (ER) if it contains key financial highlights, or more generally, a Regulatory Filing (RNS) if it's primarily operational/scientific news. Since this is a press release announcing scientific data presentation, and it does not contain the full financial results (which would suggest ER) nor is it a formal regulatory filing like a 10-K, it fits best under the general category for important company announcements that aren't covered by other specific codes. However, given the context of biotech/pharma announcements about clinical data presentations, this often falls under the broader category of significant operational news. Since there is no specific code for 'Scientific/Clinical Update Announcement', and it is not a formal report itself, RNS (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate classification, although ER is sometimes used for major data announcements. Given the focus is purely on data presentation abstracts, RNS is safer than ER, which usually implies financial results.
2022-05-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.